Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial -

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Renal and urologic disorders
Summary
Study (n=413) found 28% of treatment group had disease progression at 24 months v 58% in active surveillance group (HR 0.34, 95%CI 0.24-0.46, p<0.0001), and 49% in treatment group had a negative biopsy result vs 14% in active surveillance group (RR 3.67, 2•53–5•33; p<0•0001).
UKMi comment
An editorial discusses the questions raised by this study given that the risk of death and cancer-related morbidity for most men with low-risk prostate cancer is very low.
Related links: Comment